Showing 587 Results
Lessons from COVID-19: Step Therapy Should Not Be a Barrier to Patient Access
Step therapy requires patients to try a clinically recognized, lower cost first-line therapy before receiving reimbursement for an alternative therapy prescribed by the physician and can delay access…
A Path of Her Own: Salama Freed, 2020-22 NPC/Duke-Margolis Health Policy Fellow
Salama Freed, PhD, has always wanted to learn about the inner-world of health policy – who shapes it, what drives it and how it gets done. She believes that her path to this experience is through the…
Strategies to Optimize Medication Use
The Accountable Care Learning Collaborative (ACLC) hosted a webinar to discuss how value-minded organizations are integrating strategies to optimize medication use to lower costs and improve patient…
Accumulating Barriers to Care: Double Jeopardy for US Patients
In a column for PharmaBoardroom, Dan Leonard, National Pharmaceutical Council President and CEO, Kimberly Westrich, Vice President of Health Services Research, and Brian Sils, Senior Research…
Sustainable Solutions for Patients’ Sake
Blasine Penkowski, Chair of NPC's Board of Directors, proposes some guiding principles on how we can move toward a post-COVID world and build a more resilient system where patients have the care they…
Ready, Fire, Aim: How Not to Approach COVID Pricing Discussions
NPC raises concerns about various approaches to considering pricing for COVID-19 treatments.
CMS Proposes Changes to Medicaid Best Price
CMS announced a proposal to lift some Medicaid best price restrictions, making it easier for commercial health insurers to enter into value-based payment arrangements with biopharmaceutical…
NPC Statement on Racial, Social Injustices and Health Disparities
The recent deaths of George Floyd, Ahmaud Arbery and Breonna Taylor have put a spotlight on the racial and social injustices that are unfortunately pervasive in the United States. The COVID-19…
Evolution of the AMCP Format for Formulary Submissions: Yesterday, Today and Tomorrow
The ongoing development of vaccines and treatments for COVID-19 is raising hopes as the world awaits the return to a normal way of life. But as seen in the past decades in the fight against cancer,…
NPC in Health Affairs: It's Time to Talk COVID-19 Treatment Prices
In an article on the Health Affairs Blog, National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois considers questions about COVID-19 treatments and prices and lays out a roadmap to…
Will the Pandemic Provide the Push for Positive Change?
NPC President and CEO Dan Leonard considers the COVID-19 pandemic and its impact on our health care system, as well as whether we’ll see continued innovation in how we access, administer and pay for…
Experts Advise Including Productivity in Value Assessment Frameworks – When Included, It Can Make a Difference
NPC researchers sought to assess if productivity is included in VAF analyses, when included, does it change the value assessment of an intervention, and if including productivity could change health…
Valuing Innovation in the Current and Post-Pandemic World
Biopharmaceutical industry experts gathered for a panel discussion at the eyeforpharma Virtual Conference to explore how the value of innovation, productivity and preparedness might change as a…
New National Alliance Report Encourages Inclusion of Employer-Relevant Elements in Value Assessment
The National Alliance of Healthcare Purchaser Coalitions' report evaluated existing value frameworks and offers insights on the relationship between value assessment tools and the employer…
In Social Distancing, Finding Closeness in Community
In a video, National Pharmaceutical Council President and CEO Dan Leonard discusses social distancing and the importance of community during the COVID-19 pandemic.
Getting Value Right by Considering the Full Range of Benefits for Patients and Caregivers
A study in Health Affairs considers how health care decision-makers can incorporate the benefits associated with a medical treatment when assessing its societal value.
What's Really Behind Discrepancies in Coverage Decisions?
National Pharmaceutical Council President and CEO Dan Leonard discusses research that uncovers the reasons for discrepancies in coverage decisions.
Are Value-based Arrangements the Answer We’ve Been Waiting For?
A study by NPC suggests that while value-based arrangements can be one of many tools that payers leverage to address rising costs, it is also important to recognize the strengths and limitations…
A Conversation About Cystic Fibrosis, Caregiving and Innovation
Lisa Yourman, the mother of two adult children living with cystic fibrosis and the Coalition Chair for Action CF, discusses how advances in medicine and technology are making a difference for her…
How Do We Place a Value on Indirect Treatment Benefits Like Quality of Life?
A study from NPC and RTI Health Solutions evaluated how institutional barriers prevent the inclusion of broader individual and societal benefits associated with new health care innovations from being…